Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9577200 | 0.84 | ALDH1A1 (0.68) | TSHRNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL66631 | 0.82 | TSHR (0.62) | TSHRNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL20522284 | 0.82 | ALDH1A1 (0.70) | TSHRALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL7920724 | 0.82 | TSHR (0.67) | TSHRNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL4182181 | 0.82 | CYP3A4 (0.70) | TSHRCA1CA2CA12CA4 | |
| SCHEMBL66632 | 0.82 | CYP3A4 (0.70) | TSHRNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL1504601 | 0.82 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2AGAACA2 | |
| SCHEMBL5352151 | 0.82 | TSHR (0.62) | TSHRNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL11883523 | 0.82 | CA1 (0.68) | TSHRNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL1148808 | 0.82 | TSHR (0.67) | TSHRNPSR1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2026-03-10 | — | — | US | disclosed |
| EP-4175718-B1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIV CLAUDE BERNARD LYON (FR) | 2024-10-02 | — | — | EP | disclosed |
| CN-115843271-B | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2024-08-13 | — | — | CN | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| CN-115843271-A | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2023-03-24 | — | — | CN | disclosed |
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-0811375-B1 | GLUTAMIC ACID RECEPTOR AGONIST | NIPPON SUISAN KAISHA LTD (JP) | 2001-01-03 | — | — | EP | disclosed |
| US-5955505-A | TREATING NERVE DEGENERATIVE DISORDERS | NIPPON SUISAN KAISHA, LTD. (JP) | 1999-09-21 | — | — | US | disclosed |
| EP-0811375-A1 | GLUTAMIC ACID RECEPTOR AGONIST | NIPPON SUISAN KAISHA, LTD. (JP) | 1997-12-10 | — | — | EP | disclosed |
| EP-0469901-B1 | Sulfonamide derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5189211-A | Thromboxane A2 antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1993-02-23 | — | — | US | disclosed |
| EP-0469901-A1 | Sulfonamide derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1992-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | TSHR 3353/4885NPSR1 404/4885ALDH1A1 812/4885 |
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | CKS2, CSNK2A3, CSNK1A1L | TSHR 503/4885NPSR1 1164/4885ALDH1A1 1571/4885 |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | CSNK2A1, IDO1, CSNK2A3 | TSHR 3750/4885NPSR1 978/4885ALDH1A1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.